FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 years
read at Endpoints ↗ApprovalPositive
Egetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate.
The therapy is intended for patients with a rare X linked genetic disorder that typically limits life expectancy to about 35 years.
The FDA decision covers the use of tiratricol in the specified patient population, marking the first authorized treatment for this condition.
The approval offers a new therapeutic option for affected individuals and may open further research and market opportunities for the company.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Egetis’ Emcitate cleared by FDA for rare X-linked genetic disease”
read at Endpoints ↗80 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that